SCHEMBL18264159

SCHEMBL18264159

Nc1n[nH]c2c1c(Nc1ccc(Cl)cc1)nc1ccccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
KDM4E B2RXH2 1/20 0.52
NPC1 O15118 1/20 0.52
ALDH1A1 P00352 1/20 0.52
HPGD P15428 1/20 0.52
ALOX12 P18054 1/20 0.52
RAB9A P51151 1/20 0.52
TAAR1 Q96RJ0 1/20 0.52
NPY5R Q15761 1/20 0.50
PDE5A O76074 1/20 0.49
ABCG2 Q9UNQ0 1/20 0.49
TRPA1 O75762 1/20 0.49
ADORA3 P0DMS8 1/20 0.47
HTR2A P28223 2/20 0.45
GAA P10253 2/20 0.44
TP53 P04637 2/20 0.44
POLB P06746 1/20 0.44
ALK Q9UM73 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18264175 0.91 KDM1A (0.52) MAPTMEN1KMT2AKDM4ENPC1
SCHEMBL18264402 0.91 EGFR (0.47) MEN1KMT2ANPC1RAB9ATAAR1
SCHEMBL18264173 0.88 MEN1 (0.42) MAPTMEN1KMT2AKDM4ENPC1
SCHEMBL18264161 0.88 ABCG2 (0.51) MAPTMEN1KMT2AKDM4ENPC1
SCHEMBL18264156 0.88 NPY5R (0.50) MAPTMEN1KMT2AKDM4ENPC1
SCHEMBL18264174 0.88 GAA (0.52) MAPTMEN1KMT2AALDH1A1TAAR1
SCHEMBL18264164 0.84 ABCG2 (0.52) MEN1KMT2ARAB9AABCG2KDM1A
SCHEMBL18264154 0.84 ABCG2 (0.53) MEN1KMT2ANPC1RAB9AABCG2
SCHEMBL18264134 0.84 NPY5R (0.53) MAPTMEN1KMT2AKDM4ENPC1
SCHEMBL18264139 0.84 KDM1A (0.52) NPC1RAB9ATAAR1NPY5RABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3302060-B1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE UNIV KAOHSIUNG MEDICAL (TW) 2020-02-12 EP claimed
US-20180214426-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE KAOHSIUNG MEDICAL UNIVERSITY (TW) 2018-08-02 US claimed
EP-3302060-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE Kaohsiung Medical University (TW) 2018-04-11 EP claimed
WO-2016191576-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF β-GLUCURONIDASE DCB-USA LLC (US) 2016-12-01 WO claimed
EP-3662751-B1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF B-GLUCURONIDASE UNIV KAOHSIUNG MEDICAL (TW) 2021-10-13 EP disclosed
EP-3662751-B1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF B-GLUCURONIDASE UNIV KAOHSIUNG MEDICAL (TW) 2021-10-13 EP disclosed
US-11135206-B2 Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase KAOHSIUNG MEDICAL UNIVERSITY (TW) 2021-10-05 US disclosed
US-11135206-B2 Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase KAOHSIUNG MEDICAL UNIVERSITY (TW) 2021-10-05 US disclosed
US-11052072-B2 Pyrazolo[4,3-C] quinoline derivatives for inhibition of β-glucuronidase KAOHSIUNG MEDICAL UNIVERSITY (TW) 2021-07-06 US disclosed
US-11052072-B2 Pyrazolo[4,3-C] quinoline derivatives for inhibition of β-glucuronidase KAOHSIUNG MEDICAL UNIVERSITY (TW) 2021-07-06 US disclosed
EP-3662751-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF B-GLUCURONIDASE Kaohsiung Medical University (TW) 2020-06-10 EP disclosed
EP-3662751-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF B-GLUCURONIDASE Kaohsiung Medical University (TW) 2020-06-10 EP disclosed
EP-3302060-B1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE UNIV KAOHSIUNG MEDICAL (TW) 2020-02-12 EP disclosed
US-20180214426-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE KAOHSIUNG MEDICAL UNIVERSITY (TW) 2018-08-02 US disclosed
US-20180214426-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE KAOHSIUNG MEDICAL UNIVERSITY (TW) 2018-08-02 US disclosed
US-20180214426-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE KAOHSIUNG MEDICAL UNIVERSITY (TW) 2018-08-02 US disclosed
EP-3302060-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE Kaohsiung Medical University (TW) 2018-04-11 EP disclosed
CN-107708419-A Pyrazolo [4,3-c ] quinoline derivatives having inhibitory activity on bacterial glucuronidase 高雄医学大学 2018-02-16 CN disclosed
WO-2016191576-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF β-GLUCURONIDASE DCB-USA LLC (US) 2016-12-01 WO disclosed
WO-2016191576-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF β-GLUCURONIDASE DCB-USA LLC (US) 2016-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180214426-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE UGT1A3, UGT1A1, GUSB MAPT 4074/4885MEN1 4572/4885KMT2A 3526/4885
US-11052072-B2 Pyrazolo[4,3-C] quinoline derivatives for inhibition of β-glucuronidase UGT1A3, UGT1A1, DPP3 MAPT 4034/4885MEN1 4607/4885KMT2A 3492/4885
US-11135206-B2 Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase UGT1A3, UGT1A1, DPP3 MAPT 4034/4885MEN1 4607/4885KMT2A 3492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.